Xilio Therapeutics receives second Nasdaq deficiency letter for low stockholders' equity; bid price also non-compliant

Xilio Therapeutics, Inc.

Reported stockholders' equity of $7.069M as of June 30, 2025, below $10M minimum required for Nasdaq Global Select Market.
Company has 45 days (until Oct 6, 2025) to submit a compliance plan; Nasdaq may grant up to 180-day extension.
Also remains out of compliance with $1.00 minimum bid price requirement, initial cure period expires Oct 1, 2025.
No immediate effect on listing; company may also seek transfer to Nasdaq Capital Market.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.